Sano, Myriad Genetics withdraw proposed public offerings due to market weakness.

SANO HABITROL GENERIC COULD BE MARKETED BY PAR, if FDA approves the company's ANDA for a version of Ciba's nicotine transdermal patch for smoking cessation, according to a recent prospectus for a proposed public offering. Sano filed its ANDA in January 1995 and has "received comments from the FDA...and has responded to those comments," the prospectus states. Sano's manufacturing facilities passed an FDA preapproval inspection in July 1996.